OpGen Company Overview
About OpGen
OpGen (NASDAQ:OPGN) focuses on the development and commercialization of innovative solutions for combating infectious diseases, with an emphasis on antibiotic-resistant strains. The company pioneers cutting-edge technologies, including rapid diagnostics and informatics tools, aimed at enabling healthcare providers to quickly identify and treat infections. This endeavor significantly contributes to global health security by addressing one of the most pressing challenges in the medical field. OpGen's projects span advanced diagnostic tests and data analytics platforms, all designed to improve patient outcomes and reduce healthcare costs. Objectives revolve around expanding its product portfolio, enhancing diagnostic accuracy, and fostering partnerships to reach broader markets.
Snapshot
Operations
Products and/or services of OpGen
- Acuitas AMR Gene Panel, a rapid test for detecting antimicrobial resistance genes in bacterial isolates.
- Unyvero Platform, a comprehensive solution for infectious disease diagnostics, targeting multiple pathogens.
- Acuitas Lighthouse, a bioinformatics solution providing insights on antimicrobial resistance threats.
- Ares Genetics Database, a comprehensive repository for genetic information on antimicrobial resistance.
- QuickFISH, a rapid, molecular diagnostic test for identifying pathogens directly from patient samples.
- FISH antibiotics, providing targeted antibiotic susceptibility results to inform treatment decisions.
OpGen executive team
- Dr. Oliver Schacht Ph.D.Executive VP of Corporate Development
- Mr. Honjian TanCEO & Chairman